OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet Rheumatology is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease	573
Reigniting the burnt-out health-care workforce	530
Survivorship of revised and multiply revised knee replacements	279
Molecular signature-based decision making in the era of targeted therapies for systemic lupus erythematosus	229
COVID-19 vaccine-induced T-cell responses in patients with rheumatoid arthritis: preferential induction by ChAdOx1	186
From phenotype to pathophysiology—placing rheumatic diseases in an immunological perspective	184
A disseminated gonococcal infection with spinal locations	176
Women in rheumatology in Africa	142
Thrombotic microangiopathy as a presentation of anti-synthetase syndrome	132
Pathways driving tendinopathy and enthesitis: siblings or distant cousins in musculoskeletal medicine?	131
Can contextual factors improve clarity of the results from clinical trials of low back pain?	131
Brachial plexopathy: an unusual manifestation of Takayasu arteritis	119
Research in Brief	110
Three-dimensional, in-vitro approaches for modelling soft-tissue joint diseases	108
Acceptability of the COVID-19 vaccine among patients with chronic rheumatic diseases and health-care professionals: a cross-sectional study in 19 Arab countries	104
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?	88
Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study	86
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial	84
Biological disease-modification in axial spondyloarthritis: insights from MRI	82
Post-COVID condition in patients with inflammatory rheumatic diseases: a prospective cohort study in the Netherlands	79
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial	73
1-year results of treatment with rituximab in polymyalgia rheumatica: an extension study of a randomised double-blind placebo-controlled trial	70
Surgical microdiscectomy versus transforaminal epidural steroid injection in patients with sciatica due to lumbar disc herniation	69
Early-stage Dupuytren's disease treatment; a promising next step?	68
Interleukin-5 inhibition in eosinophilic granulomatosis with polyangiitis: time for another approach?	62

Juvenile systemic lupus erythematosus presenting as retinal vasculitis	61
Pausing drugs and spacing vaccines: an open question – Authors' reply	59
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study	57
SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study	56
Biosimilars and the era of interchangeability	55
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial	55
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis	54
Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus	53
Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis	49
Composite endpoints for Sjögren's Syndrome	49
Proof-of-concept studies in axial spondyloarthritis: there are no shortcuts	47
The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study	45
Patient-reported outcomes with anifrolumab in patients with systemic lupus erythematosus	45
Outdoor temperatures and Raynaud's phenomenon in patients with systemic sclerosis	44
Reclassifying ANCA-associated vasculitis: a focus on kidney disease	44
Research in Brief	44
Assessing glucocorticoid toxicity: are the measures sensitive enough?	43
First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study	43